Savings obtained by CA-125 measurements during therapy for ovarian carcinoma

This publication has 13 references indexed in Scilit:

• The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer
  Annals of Oncology, 1990
• CA-125 Values Predictive of Clinical Response during Second-Line Chemotherapy for Epithelial Ovarian Cancer
  American Journal of Clinical Oncology, 1989
• RANDOMISED COMPARISON OF CISPLATIN WITH CYCLOPHOSPHAMIDE/CISPLATIN AND WITH CYCLOPHOSPHAMIDE/DOXORUBICIN/ CISPLATIN IN ADVANCED OVARIAN CANCER
  The Lancet, 1987
• Evaluation of serum CA 125 levels in the monitoring of ovarian cancer
  American Journal of Obstetrics and Gynecology, 1987
• CA125 as a serum marker for poor prognosis in ovarian malignancies
  Gynecologic Oncology, 1987
• The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer
  American Journal of Obstetrics and Gynecology, 1986
• Tumour markers in germ cell tumours.
  BMJ, 1986
• High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group.
  BMJ, 1985
• Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker
  British Journal of Cancer, 1984
• A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
  New England Journal of Medicine, 1983